KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice
The Journal of Pharmacology and Experimental Therapeutics · 2025-03 · 392 (3) · 100022
DOI: 10.1124/jpet.124.002154 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-03. Verfasst von Pavel A Solopov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia. Electronic address: psolopov@odu.edu. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, National Heart Lung and Blood Institute Division of Intramural Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia. Electronic address: psolopov@odu.edu.
- Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia.
- Department of Pharmacology, School of Medicine, University of Virginia, Charlottesville, Virginia; KeViRx Inc, Charlottesville, Virginia.
- Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia; School of Medical Diagnostic & Translational Sciences, College of Health Sciences, Old Dominion University, Norfolk, Virginia.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Heart Lung and Blood Institute Division of Intramural Research
Zitieren
APA
Solopov, P. A., Colunga Biancatelli, R. M. L., Day, T., Gregory, B., Sharlow, E. R., Lazo, J. S., & Catravas, J. D. (2025). KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice. The Journal of Pharmacology and Experimental Therapeutics, 392(3), 100022. https://doi.org/10.1124/jpet.124.002154
Vancouver
Solopov PA, Colunga Biancatelli RML, Day T, Gregory B, Sharlow ER, Lazo JS, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(3):100022. doi:10.1124/jpet.124.002154
BibTeX
@article{Solopov2025,
author = {Solopov, Pavel A and Colunga Biancatelli, Ruben Manuel Luciano and Day, Tierney and Gregory, Betsy and Sharlow, Elizabeth R and Lazo, John S and Catravas, John D},
title = {KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1–induced acute lung injury in mice},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
volume = {392},
number = {3},
pages = {100022},
doi = {10.1124/jpet.124.002154}
}
EUVIMED